Gene Therapy Market to Reach $36.55 Billion by 2032, Driven by Rising Demand for Curative Treatments and Expanding Clinical Pipeline

The global gene therapy market is projected to grow from $8.85 billion in 2024 to $36.55 billion by 2032, according to MarketsandMarkets™, with a 19.4% CAGR. The report attributes growth to demand for potentially curative treatments for genetic disorders, rare diseases, and certain cancers, supported by an expanding clinical trial pipeline. It estimates that about 19 gene therapy products are expected to launch between 2026 and 2032, contributing nearly 25% of the projected market value by 2032. Key hurdles remain high treatment costs and limited manufacturing scalability. By therapeutic area, neurology leads and is expected to stay dominant, with major focus on conditions such as SMA, Duchenne muscular dystrophy and LGMD. By delivery method, in vivo dominates and is forecast for the fastest growth. North America remains the largest regional market.